Cerebrolysin side effects by evidence tier: the Cochrane finding of increased serious adverse events after stroke, the labelled reaction profile, rapid-injection effects and the gaps.
Cerebrolysin — the porcine brain-derived peptide fraction made by EVER Neuro Pharma — has more randomised trial data behind it than almost any compound in this catalogue, and the most rigorous synthesis of that data is negative on safety. The vendor description of an "excellent safety profile with only rare and mild effects" does not survive the 2023 Cochrane review. This page separates the evidence tiers — controlled trials and their systematic reviews, the approved labelling, and uncontrolled report — and lists the gaps. It is a research reference, not medical advice; the Cerebrolysin profile is the reference entry and the Cerebrolysin research overview covers the trial history.
The finding that matters is from the 2023 Cochrane review of Cerebrolysin for acute ischaemic stroke (Cochrane Database of Systematic Reviews). Pooling seven randomised trials in 1,773 participants, it concluded with moderate certainty that Cerebrolysin probably has no beneficial effect on all-cause death, and found an increase in non-fatal serious adverse events, risk ratio 2.39, also at moderate certainty. That is a doubling of serious harm without a mortality benefit, in the best-controlled evidence the compound has.
The largest trial in that pool, CASTA (Heiss and colleagues, Stroke, 2012), gave 1,070 stroke patients 30 mL daily by intravenous infusion for 10 days and found no difference on its primary outcome. The CARS recovery trial (Muresanu and colleagues, Stroke, 2016; 208 patients, 30 mL daily for 21 days) was sized for efficacy, not safety.
The 2019 Cochrane review of vascular dementia (six trials, 597 participants) rated every primary outcome as very-low-certainty evidence, citing risk of bias, unexplained heterogeneity and industry funding. Those limitations apply to its adverse-event data as much as to its efficacy data; a low event count in poorly reported trials is not reassurance. The Alzheimer's evidence is a 2015 meta-analysis (Gauthier and colleagues, Dementia and Geriatric Cognitive Disorders) of small, partly manufacturer-associated trials, and the traumatic-brain-injury literature (the CAPTAIN trials, 2020) rests substantially on observational data.
Because Cerebrolysin is licensed in Austria and elsewhere, it carries a product label with pharmacovigilance frequency categories — a stronger source than any research-market compound has, though post-marketing frequencies undercount.
Very rare (fewer than 1 in 10,000): hypersensitivity reactions including tingling, skin and local vascular reactions, neck, head and limb pain, fever, dyspnoea, chills and shock-like states; single reported cases of grand mal seizures; palpitations or arrhythmia on too-rapid administration; nausea, vomiting, diarrhoea, constipation and dyspepsia; and injection-site redness, itching and burning.
Rare (between 1 in 10,000 and 1 in 1,000): loss of appetite; agitation, including aggressiveness, confusion and insomnia, described as an extension of the intended activating effect; dizziness and a sensation of heat or sweating, particularly on rapid injection; and pruritus.
The labelling contraindicates hypersensitivity, status epilepticus and severe renal impairment; specifies caution in allergic diathesis and in epilepsy, where seizure frequency may increase; does not recommend use under 18 years; and flags additive effects with antidepressants and MAO inhibitors. It also lists physical incompatibility with lipid-containing solutions, balanced amino-acid solutions and any solution outside pH 5.0–8.0.
Several labelled reactions — palpitations, arrhythmia, heat, sweating, dizziness — are tied to rapid injection, which is why larger volumes are diluted and infused over 15–60 minutes, with undiluted intravenous injection capped at 10 mL and intramuscular injection at 5 mL. Every trial used those routes. Subcutaneous administration appears in none of the labelling and none of the trials, so there is no safety data of any kind for that route.
The controlled record describes a licensed solution, given intravenously or intramuscularly under medical supervision, to patients with stroke, dementia or brain injury, for 10 to 28 days. None of it covers:
Community and vendor reports describe injection-site pain, headache, flushing and restlessness — recognisably the labelled profile, but uncontrolled self-report with no denominator, useless for incidence or causation.
Cerebrolysin is a porcine-derived biological, which brings questions a synthetic peptide does not: source animal, sterility and endotoxin load. The licensed manufacturer answers them through a regulated process; a research-market supplier can only answer them by testing. A certificate of analysis for a peptide mixture cannot report purity by HPLC the way a single peptide's can — what it can report is total peptide content, amino-acid profile, sterility and endotoxin, and lab testing and COAs explains what to look for. Storage is a further confound: the licensed solution is kept below 25 °C, never refrigerated or frozen, the inverse of the cold-chain and shelf-life guide, so material handled by peptide rules was stored against its label. A powder of unstated provenance carries none of the safety data on this page.
Cerebrolysin has no market authorisation from Health Canada — no Drug Identification Number and no approved product monograph — and Health Canada has issued advisories about injectable products purchased online. It is not FDA-approved. It is an approved prescription medicine in Austria and registered in Russia, China and other markets. It is not scheduled under the Controlled Drugs and Substances Act and is listed in Canada, as on the Cerebrolysin product page, for laboratory research only. It is not named on the WADA Prohibited List; its Austrian approval keeps the licensed product outside category S0 on its plain text, though that argument does not extend to a research powder, and section S2 carries a case-by-case catch-all for growth factors and their modulators. Tested athletes should confirm status with their own anti-doping organisation.
What is the most important Cerebrolysin safety finding? The 2023 Cochrane review of seven stroke trials in 1,773 participants found an increase in non-fatal serious adverse events (risk ratio 2.39) with no effect on death from any cause, both at moderate certainty. It is the largest controlled dataset the compound has.
What side effects does the labelling list? Very rare hypersensitivity reactions up to shock-like states, single cases of seizures, palpitations or arrhythmia on rapid injection, gastrointestinal upset and injection-site reactions; rare loss of appetite, agitation, confusion, insomnia, dizziness and pruritus. It contraindicates status epilepticus and severe renal impairment.
Is Cerebrolysin safe to combine with other compounds? The labelling flags additive effects with antidepressants and MAO inhibitors and incompatibility with lipid and amino-acid solutions. No study has combined it with Semax, Selank or any other research peptide; nothing here is a safety claim.
Does the safety data apply to a powder sold as Cerebrolysin? No. No authorised powder exists; the licensed product is a solution at 215.2 mg/mL. A powder is a different preparation whose composition, sterility and endotoxin status must be established on their own.
Is this medical advice? No. This page reports the published adverse-event literature and the approved labelling for researchers. Cerebrolysin is unapproved in Canada and listed here for laboratory research only, not for human or veterinary use.
